

## **Aldeyra Therapeutics Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 26-Apr-2015

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 8

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 15

[Return to Table of Contents](#)

# Aldeyra Therapeutics Inc

## COMPANY OVERVIEW

Company Name	Aldeyra Therapeutics Inc
Parent Company Name	Aldeyra Therapeutics Inc
Website	<a href="http://www.aldeyra.com/">http://www.aldeyra.com/</a>
Country	US
Number of Drugs in Active Development	2
Number of Inactive Drugs	1
Number of Patents as Owner	6
Number of Patents as Third Party	0
Number of Deals	3
Key Indications	Uveitis, Autosomal recessive disorder, Macular degeneration, Age related macular degeneration, Atherosclerosis, Atopic dermatitis, Cataract, Diabetes mellitus, Metabolic syndrome X, Parkinsons disease, Retinopathy, Rheumatoid arthritis, Sepsis, Stargardt disease, Toxicity
Key Target-based Actions	Unspecified receptor antagonist, CXC9 chemokine ligand inhibitor, IL-12 antagonist, IL-17 antagonist, IL-5 antagonist, Interleukin-1 beta ligand inhibitor, Leukemia inhibitory factor antagonist, Mitochondrial intermediate peptidase inhibitor, Monocyte chemotactic protein 1 ligand inhibitor, TNF
Key Technologies	Small molecule therapeutic, Ophthalmic formulation, Ophthalmic liquid formulation, Dermatological formulation, Emulsion dermatological, Transdermal formulation, Condensational synthesis, Nucleophilic substitutional synthesis, Salt synthesis

## COMPANY PROFILE

### SUMMARY

Aldeyra Therapeutics Inc (formerly Aldexa Therapeutics Inc; Neuron Systems Inc), a biotechnology company incorporated in 2004, focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules.

### FINANCIAL

In January 2015, the company entered into a definitive purchase agreement to raise about \$2 million in a private placement of common stock and a warrant to purchase up to 211,528 shares of common stock each at a price of \$0.125. The exercise price of the three-year warrant was \$9.50 per share. Aldeyra might redeem the warrants at a price of \$0.001 per share upon notice to the holders, when the company's common stock for each of the 15 consecutive trading days prior to such redemption would at least be \$20 per share and the average trading volume of company's common stock during such period would be 50,000 shares per day. At that time, the company also agreed to sell an aggregate of 211,528 shares each at a price of \$9.33. Later that month, the private placement was completed.

In January 2015, the company entered into a definitive purchase agreement to raise approximately \$7.79 million in a private placement of common stock and warrants and also agreed to sell an aggregate of approximately 1.1 million shares of common stock at a price of \$7.00 per share and at an exercise price of \$9.50 to the investors. At that time, the warrants would expire in three years from the date of issue and also the company was required to file a registration statement for the resale of the shares of common stock issued and issuable pursuant to the warrants. The closing of the offering was subjected to the satisfaction of customary closing conditions; later that month, the offering was closed. Aldeyra might redeem the warrants at a price of \$0.001 per share upon notice to the holders, when the company's common stock for each of the fifteen consecutive trading days prior to such redemption would at least be \$20.00 per share and the average trading volume of company's common stock during such period would be 50,000 shares per day.

In June 2014, the company was added to the Russell Microcap Index.

In May 2014, Aldeyra was to raise gross proceeds of \$12 million from an IPO of 1.5 million common stock shares priced at \$8 each. The underwriters were granted a 45-day overallotment option to purchase up to 225,000 additional common

[Return to Table of Contents](#)



stock shares. At that time, the shares began trading on the NASDAQ Capital Market under the ticker symbol 'ALDX'. The offering closed later that month and the company raised net proceeds of \$11 million.

COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	9.56
Change (USD)	-0.18 (-1.85%)
Previous Close Price (USD)	9.74
Volume	5,974
52-Week High (USD)	13.50
52-Week Low (USD)	3.00
Date	24-Apr-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	5,565,415
Current Market Capitalization	65,868,620
EPS (Date Reported)	-2.50747

[Return to Table of Contents](#)

## STOCK PERFORMANCE



## MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Fidelity Select Biotechnology Portfolio	Mutual Fund	United States	556,516	8.08	0	0	28-Feb-2015
Fidelity Advisor Biotechnology Fund	Mutual Fund	United States	278,295	4.04	0	0	28-Feb-2015
Fidelity Spartan Extended Market Index Fund	Mutual Fund	United States	22,558	0.33	0	0	28-Feb-2015
Clarke (C Boyd)	Individual Investor	United States	15,500	0.22	15,500	1	31-Mar-2015
Brady (Todd C)	Individual Investor	United States	15,089	0.22	12,500	4.83	31-Mar-2015
Joyce (Martin J)	Individual Investor	United States	13,500	0.2	13,500	1	31-Mar-2015
Bronstein Ben	Individual Investor	United States	12,500	0.18	12,500	1	31-Mar-2015
Phillips Gary M	Individual Investor	United States	9,375	0.14	9,375	1	31-Mar-2015
The Vanguard Group, Inc.	Investment	United States	8,198	0.12	3,200	0.64	31-Mar-2015


[Return to Table of Contents](#)



	Advisor						
Walker Neal	Individual Investor	United States	6,250	0.09	6,250	1	31-Mar-2015
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	4,198	0.06	3,400	4.26	31-Mar-2015
Vanguard US Equity Index Fund	Mutual Fund	United States	3,800	0.06	-400	-0.1	28-Feb-2015
AXA/Lord Abbett Micro Cap Portfolio	Mutual Fund	United States	269	0	0	0	28-Feb-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	200	0	200	1	28-Feb-2015

## FINANCIAL PERFORMANCE

### Sales and Income



	2011	2012	2013	2014
<b>Sales (USD M)</b>	0	0	0	0
<b>Operating Income (USD M)</b>	-2.108539	-1.114211	-3.676407	-7.27059
<b>Net Income (USD M)</b>	-2.5931	-23.464002	1.10991	-9.573911

[Return to Table of Contents](#)

## Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q4	0	-2.411044	-2.444679
2014 Q3	0	-1.968135	-2.009206
2014 Q2	0	-1.646487	-5.330228
2014 Q1	0	-1.244924	-0.013237
2013 Q4	0	-1.232723	0.794321
2013 Q3	0	-1.166456	0.87752
2013 Q2	0	-0.98569	-1.718878
2013 Q1	0	-0.291538	-4.098092
2012 Q4	0	-0.116421	-37.627267

## BALANCE SHEET

### Assets (USD M)

	2011	2012	2013	2014
Cash & Short Term Investments	0.250955	1.223638	3.262354	8.527304
Inventories - Total	0	0	0	0
Current Assets - Total	0.255167	1.977024	3.270766	8.759872
Property, Plant And Equipment - Net	0.003737	0	0	0.012993
Other Assets - Total	0	0	0.472467	0.014238
Total Assets	0.258904	1.977024	3.743233	8.787103

### Liabilities (USD M)

	2011	2012	2013	2014
Accounts Payable	0.025298	0.072538	0.341853	0.341294
Short Term Debt & Current Portion Of Long Term Debt	2.2	0.166667	0.14316	0.077546
Current Liabilities - Total	2.593452	0.363433	0.605011	1.327564
Long Term Debt	0	24.587753	1.382262	1.175481
Other Liabilities	0	2.1805	3.659988	0
Total Liabilities	2.593452	27.131686	5.647261	2.503045

[Return to Table of Contents](#)



## Stockholders Equity (USD M)

	2011	2012	2013	2014	
Minority Interest	0	0	0	0	
Preferred Stock	13.178449	29.229834	38.317298	0	
Common Stock	0.003773	0.003773	0.000327	0.005565	
Treasury Stock			0		
Total Liabilities & Shareholders' Equity	0.258904	1.977024	3.743233	8.787103	

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-1.62	-1.6	-1.61
31-Dec-2016	-1.92	-1.64	-2.04
31-Dec-2017	-2.31	-2.23	-1.62

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015			-10.72	0
31-Dec-2016			-15.72	0.5
31-Dec-2017			-10.85	6.67

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Ocular disease	1	1	2
Genetic disorder	1	0	1
Inflammatory disease	1	0	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	2
No Development Reported	1

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Early Research/Development	0	0	1	0	1
Drug - Development Services	0	0	1	0	1
Technology - Delivery/Formulation	0	0	1	0	1

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Dermatological disease	1	1
Ocular disease	1	1

[Return to Table of Contents](#)

Inflammatory disease	1	1
----------------------	---	---

## Trials by Phase

Phase	Ongoing	All
Phase 2	2	2

## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	1	0	1
Endocrine disease	1	0	1
Gastrointestinal disease	1	0	1
Immune disorder	1	0	1
Musculoskeletal disease	1	0	1
Ocular disease	6	0	6
Metabolic disorder	1	0	1
Neurological disease	1	0	1
Infectious disease	1	0	1
Toxicity and intoxication	1	0	1
Inflammatory disease	1	0	1
Dermatological disease	1	0	1

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)



## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### NS-2 (eye drops, uveitis), Aldeyra

<b>Drug Name</b>	NS-2 (eye drops, uveitis), Aldeyra
<b>Key Synonyms</b>	
<b>Originator Company</b>	Aldeyra Therapeutics Inc
<b>Active Companies</b>	Aldeyra Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Uveitis
<b>Target-based Actions</b>	
<b>Other Actions</b>	Anti-inflammatory, Unspecified drug target
<b>Technologies</b>	Ophthalmic formulation, Ophthalmic liquid formulation, Small molecule therapeutic
<b>Last Change Date</b>	27-Mar-2015

### NS-2 (topical cream formulation, Sjogren-Larsson Syndrome), Aldeyra Therapeutics

<b>Drug Name</b>	NS-2 (topical cream formulation, Sjogren-Larsson Syndrome), Aldeyra Therapeutics
<b>Key Synonyms</b>	
<b>Originator Company</b>	Aldeyra Therapeutics Inc
<b>Active Companies</b>	Aldeyra Therapeutics Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Autosomal recessive disorder
<b>Target-based Actions</b>	
<b>Other Actions</b>	Unspecified drug target, Anti-inflammatory
<b>Technologies</b>	Transdermal formulation, Dermatological formulation, Emulsion dermatological, Small molecule therapeutic
<b>Last Change Date</b>	03-Apr-2015

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)